22876-64-8

Basic information

• Product Name: Ethanamine, 2-[[(4-methoxyphenyl)methyl]thio]-
• CAS NO: 22876-64-8
• Molecular Formula: C10H15NOS
• Molecular Weight: 197.301
• Mol File: 22876-64-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Ethanamine, 2-[[(4-methoxyphenyl)methyl]thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanamine, 2-[[(4-methoxyphenyl)methyl]thio]-(22876-64-8)
• EPA Substance Registry System: Ethanamine, 2-[[(4-methoxyphenyl)methyl]thio]-(22876-64-8)

Safety Data

• Hazardous Substances Data: 22876-64-8(Hazardous Substances Data)

Upstream product

• 156-57-0 2-mercaptoethylamine hydrochloride 
• 824-94-2 p-methoxybenzyl chloride 
• 60-23-1 Cysteamine 

Downstream Products

• 53492-58-3 3-<2-<(4-methoxyphenyl)thio>ethyl>-4-methylsydnone 
• 54785-27-2 3-[2-(4-methoxy-benzylsulfanyl)-ethyl]-4-methyl-sydnone 
• 189950-03-6 (1R,2S,3S,5S)-3-(4-Chloro-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid [2-(4-methoxy-benzylsulfanyl)-ethyl]-amide 
• 189950-04-7 (1R,2S,3S,5S)-3-(4-Fluoro-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid [2-(4-methoxy-benzylsulfanyl)-ethyl]-amide 
• 185348-36-1 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid [2-(4-methoxy-benzylsulfanyl)-ethyl]-amide 
• 189950-27-4 N,N'-bis-[2-(4-methoxy-benzylsulfanyl)-ethyl]-ethylenediamine 
• 1147093-54-6 2-{(2-chloroacetyl)-[2-(4-methoxy-benzylsulfanyl)-ethyl]-amino}-2-(4-chlorophenyl)-N-cyclohexyl-acetamide 
• 1426262-78-3 C₂₇H₂₈FN₃O₄S₂ 
• 1426262-77-2 C₂₇H₂₉N₃O₄S₂ 
• 1426263-28-6 C₂₄H₂₃N₃O₄S₂ 
• 1426263-27-5 C₂₃H₂₀FN₃O₃S₂ 
• 1426263-26-4 C₂₃H₂₁N₃O₃S₂ 
• 1426263-23-1 C₃₃H₃₂FN₃O₃S₃ 
• 1426263-22-0 C₃₃H₃₃N₃O₃S₃ 

Relevant articles and documents

Synthesis, silver (I) extraction and silver (I) binding studies of novel N 1,N 3-bis(2-(benzylthio)ethyl)propanediamide derivatives

Abstract: Solvent or liquid–liquid extraction represents a highly valuable technique for the selective recovery of metals from the aqueous phase due to the ease of operation and short turnaround times. Ligands bearing soft donor atoms including nitrogen and sulfur are ideal candidates for selective silver recovery due to their preference for silver binding. Herein, novel N1,N3-bis(2-(benzylthio)ethyl)propanediamide derivatives bearing sulfur and nitrogen donor atoms were prepared in low to high yields and tested for Ag+ extraction from ternary aqueous solutions also containing Cu2+ and Pb2+ following a well-established solvent extraction protocol. It was observed that electronics effects at the 4-aryl position in the propanediamide (or malondiamide) derivatives had a significant effect on the selectivity, but little effect on the efficiency of Ag+ extraction with the 4-methoxy analogue proving the most selective. Steric hindrance provided by dimethyl substitutions at the α-positions to the sulfur atoms had negative effects on Ag+ extraction efficiency and selectivity, while diethyl steric hindrance at the methylene center lowered selectivity but increased extraction efficiency for Ag+. Detailed binding studies reveal that one of the malondiamide derivatives which lacked the electronic and steric hindrance groups studied coordinated Ag+ in a 1:1 fashion suggesting a tetrahedral complex geometry. Overall, the results show that simple modification of the electronics and sterics of the N1,N3-bis(2-(benzylthio)ethyl)propanediamides, can improve their selectivity for Ag+ recovery from the aqueous phase. Graphic abstract: [Figure not available: see fulltext.].

INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS

The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

AGENTS FOR IMAGING AND DIAGNOSTIC METHODS USING THEM

The present invention provides novel compounds that bind selectively to cells undergoing perturbations and alterations of the normal organization of their plasma membrane, while binding to a lesser degree to cells having membranes of normal organization,